“…Hence, in spite of the efforts of currently available pharmacological options to keep the disease under control, MG patients show anyhow a poorer QoL, due to physical disability with its negative rebounds on daily activities [ 4 , 19 ]. MG imposes a considerable economic burden, especially for patients that present myasthenic crises and severe complications [ 20 ].…”